CoChat

Trastuzumab Triggers Phagocytic Killing of High HER2 Cancer Cells In Vitro and In Vivo by Interaction with Fcγ Receptors on Macrophages

The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.

Abstract

Trastuzumab has been used for the treatment of HER2-overexpressing breast cancer for more than a decade, but the mechanisms of action for the therapy are still being actively investigated. Ab-dependent cell-mediated cytotoxicity mediated by NK cells is well recognized as one of the key mechanisms of action for trastuzumab, but trastuzumab-mediated Ab-dependent cellular phagocytosis (ADCP) has not been established. In this study, we demonstrate that macrophages, by way of phagocytic engulfment, can mediate ADCP and cancer cell killing in the presence of trastuzumab. Increased infiltration of macrophages in the tumor tissue was associated with enhanced efficacy of trastuzumab whereas depletion of macrophages resulted in reduced antitumor efficacy in mouse xenograft tumor models. Among the four mouse FcγRs, FcγRIV exhibits the strongest binding affinity to trastuzumab. Knockdown of FcγRIV in mouse macrophages reduced cancer cell killing and ADCP activity triggered by trastuzumab. Consistently, an upregulation of FcγRIV expression by IFN-γ triggered an increased ADCP activity by trastuzumab. In an analogous fashion, IFN-γ priming of human macrophages increased the expression of FcγRIII, the ortholog of murine FcγRIV, and increased trastuzumab-mediated cancer cell killing. Thus, in two independent systems, the results indicated that activation of macrophages in combination with trastuzumab can serve as a therapeutic strategy for treating high HER2 breast cancer by boosting ADCP killing of cancer cells.

Overview

Integrity signals

Registry

Crossref · 10.4049/jimmunol.1402891

Cites

40 of 40 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

2 retracted

Show all 40 references

Cited by

Items 101–200 of 202

Metadata

Authors
Shi, Y., Fan, X., Deng, H., Brezski, R. J., Rycyzyn, M., Jordan, R. E., Strohl, W. R., Zou, Q., Zhang, N., & An, Z.
Affiliations
  • Army Medical University (CN)
  • Brown Foundation Institute of Molecular Medicine for the Prevention of Human Diseases (US)
  • Janssen Research & Development (United States) (US)
Corresponding author
  • Shi, Yun
  • Fan, Xuejun
  • Deng, Hui
  • Zhang, Ningyan
  • An, Zhiqiang
Venue
The Journal of Immunology
Published
2015-05-01
Volume
194
Issue
9
Pages
4379-4386
ISSN
  • 0022-1767 (ISSN-L)
  • 1550-6606
OpenAlex
W1589766395
Cited by
195
References
40
Citations by year
2026: 9 · 2025: 18 · 2024: 22 · 2023: 19 · 2022: 27 · 2021: 23 · 2020: 20 · 2019: 16 · 2018: 13 · 2017: 19 · 2016: 6 · 2015: 3
FWCI
11.08
Type
journal article
Language
en
Open access
closed
Locations
  • The Journal of Immunology (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
  • Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
  • Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
Keywords
trastuzumab, HER2-positive breast cancer, antibody-dependent cellular phagocytosis, macrophages, Fc gamma receptor, FcγRIV, FcγRIII, interferon-gamma, macrophage activation, tumor-associated macrophages, phagocytic killing, antitumor immunity
MeSH terms
Trastuzumab, Animals, Antibody-Dependent Cell Cytotoxicity, Antineoplastic Agents, Cytotoxicity, Immunologic, Disease Models, Animal, Humans, Macrophages, Neoplasms, Phagocytosis, Gene Expression, Receptors, IgG, Erb-b2 Receptor Tyrosine Kinases, Receptor, ErbB-2, Cell Line, Tumor, Mice, Antibodies, Monoclonal, Humanized, Heterografts

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.